Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (G-202-003)

This study is currently recruiting participants.
Verified April 2014 by GenSpera, Inc.
Sponsor:
Information provided by (Responsible Party):
GenSpera, Inc.
ClinicalTrials.gov Identifier:
NCT01777594
First received: January 18, 2013
Last updated: April 11, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)